Open AccessFunctional neuroimaging using F-18 FDG PET/CT in amnestic mild cognitive impairment: A preliminary study
Author(s) -
Madhavi Tripathi,
Rajnish Sharma,
Abhinav Jaimini,
Maria MD'Souza,
Sanjiv Saw,
Anupam Mondal,
Suman Kushwaha
Publication year - 2013
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/0972-3919.119538
Subject(s) - medicine , statistical parametric mapping , dementia , positron emission tomography , neuroimaging , neuropsychology , memory clinic , magnetic resonance imaging , neurology , audiology , cognition , psychiatry , nuclear medicine , disease , radiology
People with amnestic mild cognitive impairment (aMCI) are at a higher risk of developing Alzheimers Dementia (AD) than their cognitively normal peers. Decreased glucose metabolism with F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is a downstream marker of neuronal injury and neurodegeneration. The risk of developing AD is higher in patients with aMCI who have a pattern of AD related glucose metabolic changes on FDG-PET than those who do not have these changes. We evaluated the utility of visual and 'statistical parametric mapping (SPM)-supported reading' of the FDG-PET scans of patients clinically classified as aMCI for identification of predementia patterns and for prediction of their progression to AD (PTAD).